Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
Toxicology and Applied Pharmacology
|
January 9, 2007
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma
Paul B Fisher, Devanand Sarkar, Irina V Lebedeva, et al.
Molecular Cancer Therapeutics
|
May 8, 2007
p53 therapy in a patient with Li-Fraumeni syndrome
Neil Senzer, John Nemunaitis, Michael Nemunaitis, et al.
Gynecologic Oncology
|
March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer
Rodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Gynecologic Oncology
|
December 1, 2022
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]
Rodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Gene Regulation and Systems Biology
|
October 20, 2009
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2
Anagha P Phadke, Chris Jay, Salina J Chen, et al.
Oncology
|
June 28, 2014
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver
John Nemunaitis, Minal Barve, Douglas Orr, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 29, 2015
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
Maurizio Ghisoli, Minal Barve, Reva Schneider, et al.
The Journal of Gene Medicine
|
May 5, 2010
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy
Gregory Nemunaitis, Phillip B Maples, Chris Jay, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 26, 2009
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors
John Nemunaitis, Alex W Tong, Michael Nemunaitis, et al.
Cancer
|
May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
Andrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
Toxicology and Applied Pharmacology
|
January 9, 2007
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma
Paul B Fisher, Devanand Sarkar, Irina V Lebedeva, et al.
Molecular Cancer Therapeutics
|
May 8, 2007
p53 therapy in a patient with Li-Fraumeni syndrome
Neil Senzer, John Nemunaitis, Michael Nemunaitis, et al.
Gynecologic Oncology
|
March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer
Rodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Gynecologic Oncology
|
December 1, 2022
Corrigendum to "Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer" [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]
Rodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Gene Regulation and Systems Biology
|
October 20, 2009
Safety and in vivo expression of a GNE-transgene: a novel treatment approach for hereditary inclusion body myopathy-2
Anagha P Phadke, Chris Jay, Salina J Chen, et al.
Oncology
|
June 28, 2014
Summary of bi-shRNA/GM-CSF augmented autologous tumor cell immunotherapy (FANG™) in advanced cancer of the liver
John Nemunaitis, Minal Barve, Douglas Orr, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 29, 2015
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
Maurizio Ghisoli, Minal Barve, Reva Schneider, et al.
The Journal of Gene Medicine
|
May 5, 2010
Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy
Gregory Nemunaitis, Phillip B Maples, Chris Jay, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
November 26, 2009
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors
John Nemunaitis, Alex W Tong, Michael Nemunaitis, et al.
Cancer
|
May 19, 2012
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
Andrew J Wagner, John M Goldberg, Steven G Dubois, et al.
Page
of 8